December 3, 2025 AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer’s disease
October 14, 2025 Response letter to previous article published about Alzstatin’s unique mode of action against Alzheimer’s
September 8, 2025 Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025
September 4, 2025 Data from AlzeCure’s pain project ACD440 presented at the NeuPSIG 2025 pain conference
August 19, 2025 AlzeCure Pharma livestreams event about the pain project ACD440 and the opportunities within orphan drugs
August 5, 2025 New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference
July 29, 2025 New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain
June 12, 2025 AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease
April 7, 2025 New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer’s conference
April 2, 2025 New scientific article in Nature linking the potential use of NeuroRestore ACD856 for the treament of obesity
February 24, 2025 New article showing the unique mechanism of action behind Alzstatin as an Alzheimer’s treatment
February 17, 2025 AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease
January 21, 2025 AlzeCure receives abstract acceptance at Alzheimer’s congress AD/PD 2025 on NeuroRestore ACD856
